DexCom earnings beat by $0.03, revenue topped estimates
On Tuesday, JMP Securities sustained its Market Perform rating on Avanos Medical (TASE:BLWV), a company trading on the New York Stock Exchange under the ticker (NYSE:AVNS), following the release of its first-quarter 2025 financial results. Avanos Medical’s revenue for the quarter exceeded Wall Street predictions by approximately 4%, marking a modest year-over-year growth of 1%. This figure adjusts to a 3% increase when considering currency fluctuations and the exclusion of strategic product exits. The adjusted earnings per share (EPS) for the quarter stood at $0.26, which is above both the consensus estimate and JMP Securities’ forecast of $0.18, as well as the $0.22 reported in the first quarter of 2024. According to InvestingPro data, the company maintains a healthy financial position with a current ratio of 2.57, indicating strong liquidity, and operates with a moderate debt-to-equity ratio of 0.17.
Despite the better-than-expected quarterly performance, Avanos Medical’s management has maintained its revenue forecast for the full year, expecting a range between $665 million and $685 million, which would represent a roughly 2% decline from the previous year. However, the company has revised its full-year 2025 adjusted EPS guidance downwards to an approximate midpoint of $0.85 from the previously projected midpoint of around $1.15. The adjustment in the EPS outlook is attributed to the anticipated impact of tariffs, estimated at $15 million, which are expected to start affecting the company’s financials from the second quarter of 2025. InvestingPro analysis suggests the stock is currently undervalued, with a strong free cash flow yield of 19% and several positive indicators available to Pro subscribers.
The analyst at JMP Securities, David Turkaly, provided insights into the company’s performance and future expectations. Turkaly highlighted that the first-quarter results showed resilience, with earnings surpassing the consensus and JMP Securities’ own estimates. Nevertheless, the full-year guidance adjustment reflects the challenges Avanos Medical anticipates due to the tariff impact.
Avanos Medical’s financial update comes at a time when the company is navigating a complex global economic landscape. With the reaffirmed Market Perform rating, JMP Securities signals a neutral stance on the stock, indicating that the firm believes the stock is fairly valued at its current price, taking into account the company’s recent performance and future earnings expectations as outlined by the management.
In other recent news, Avanos Medical Inc. reported a strong financial performance for the first quarter of 2025, surpassing analyst expectations. The company achieved an earnings per share (EPS) of $0.26, exceeding the forecasted $0.18, and generated revenue of $167.5 million, surpassing the anticipated $162 million. Avanos highlighted successful product innovation and international expansion as key contributors to this growth. The company maintains its full-year revenue estimate between $665 million and $685 million, with adjusted EPS projected between $0.75 and $0.95. Additionally, Avanos has been actively managing tariff-related costs and plans to transition manufacturing out of China by the first half of 2026. The company’s Specialty Nutrition Systems and Pain Management segments showed strong performance, contributing to overall growth. Analysts from Stifel noted the company’s positive start to the year and emphasized the importance of strategic focus and execution consistency. Avanos continues to explore strategic mergers and acquisitions to support its growth strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.